Cancer Type: Gastrointestinal

For more information about any of the clinical trials listed on this site, call 314-747-7222 or 800-600-3606 toll free or email

Select Basic Search to view clinical trials grouped by category and Advanced Search to be able to further narrow search results.



A Multi-Center, Open-Label, Phase 1/1b Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anticancer Activity of Fruquintinib in Patients with Advanced Solid Tumors


A Phase 1/2, First-in-Human, Open-label, Dose Escalation Study of GB1275 Monotherapy and in Combination with an Anti-PD-1 Antibody in Patients with Specified Advanced Solid Tumors or in Combination with Standard of Care in Patients with Metastatic Pancreatic Adenocarcinoma, Followed by Basket Expansion of GB1275 with Standard of Care or in Combination with an Anti-PD-1 Antibody in Patients with Specified Metastatic Solid Tumors


A Phase 1 Multicenter Global First in Human Study of the CD73 Inhibitor LY3475070 as Monotherapy or in Combination with Pembrolizumab in Patients with Advanced Solid Malignancies


First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors


A Phase I Open Label, Clinical Trial Evaluating the Safety and Anti-tumor Activity of Autologous T Cells Expressing Enhanced TCRs Specific for Alpha-fetoprotein (AFPc332T) in HLA-A2 Positive Subjects with Advanced Hepatocellular Carcinoma (HCC) or Other AFP Expressing Tumour Types


A Phase 1/2a Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN536 in Patients with Advanced Cancers Associated with Mesothelin Expression Who Have Failed Standard Available Therapy


Ramucirumab plus irinotecan in patients with previously treated advanced gastric or gastro-esophageal junction adenocarcinoma


A Multicenter Pilot Study of Nivolumab with Drug Eluting Bead Transarterial Chemoembolization in Patients with Advanced Hepatocellular Carcinoma


A Phase II Study of Proton Beam Therapy in the Treatment of Esophageal Cancer


A phase I/II study to evaluate the tolerability and efficacy of BMS-813160 (CCR2/5 inhibitor) with nivolumab and gemcitabine and nab-paclitaxel in borderline resectable and locally advanced pancreatic ductal adenocarcinoma (PDAC)